收藏切换
Clinical research of recombinant human prourokinase in the treatment of acute pulmonary embolism
收藏切换
Qin-qin ZHANG1, 2, Zong-an LIANG1, *, Xian-mei QIN2
World Clinical Drug | 2018, 39(5) : 313 - 317
Less
收藏切换
World Clinical Drug | 2018, 39(5): 313-317
• Article •
Clinical research of recombinant human prourokinase in the treatment of acute pulmonary embolism
Full
Qin-qin ZHANG1, 2, Zong-an LIANG1, *, Xian-mei QIN2
Affiliations
  • 1.Department of Respiratory and Critical Medical, West China School of Medicine/West China Hospital, Sichuan University, Chengdu 610041
  • 2.Department of Respiratory Medicine, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China
Published: 2018-05-10 doi: 10.13683/j.wph.2018.05.006
Outline
收藏切换
Objective

To study the efficacy and safety of recombinant human prourokinase in the treatment of acute pulmonary embolism (APE).

Methods

A total of 78 cases of APE patients from September 2015 to August 2016 admitted were divided into observation group and control group according to the order of admission. The observation group was received recombinant human prourokinase, and the control group was given urokinase for treatment. The total effective rates of the two groups were calculated, and the blood gas, blood pressure, coagulation and the fibrinolysis related indexes of two groups before and after treatment were compared. The incidences of adverse drug reactions in two groups were observed.

Results

After treatment, the total effective rate of the observation group was higher than that of the control group (89.74% vs 61.54%, P<0.05). Compared with before treatment, the blood gas, blood pressure, coagulation and the fibrinolysis related indexes of two groups after treatment were improved (P<0.01). The arterial oxygen pressure and systolic blood pressure in observation group were higher than those in control group [(88.96±8.43) mmHg, (132.98±14.65) mmHg vs (78.98±7.87) mmHg, (122.97±12.89) mmHg](P<0.05, P<0.01), and the pulmonary artery systolic pressure was lower than that of control group [(32.98±3.84) mmHg vs (45.98±4.87)mmHg](P<0.01). The tissue type plasminogen activator, plasminogen activator inhibitor-1, coagulation regulator protein, protein C, protein S, plasma D-dimer (DD) in observation group were lower than those in control group [(6.04±0.61) μg/L, (48.21±4.25) μg/L, (3.51±0.32) μg/L, (2.14±0.26) mg/L (13.56±1.46) mg/L, and (0.72±0.04) mg/L vs (9.87±0.93) μg/L, (54.32±5.11) μg/L, (5.15±0.53) μg/L, (3.24±0.37) mg/L, (19.58±1.94) mg/L, and (1.03±0.09) mg/L](P<0.01). The adverse drug reaction rate in observation group was lower than that in control group (7.69% vs 35.90%, P<0.05).

Conclusion

Recombinant human prourokinase is effective in the treatment of APE. It can effectively improve blood gas, blood pressure, coagulation and the fibrinolysis related indexes, and has less adverse drug reactions such as bleeding.

recombinant human prourokinase  /  acute pulmonary embolism (APE)  /  curative effect  /  adverse drug reaction
张琴琴, 梁宗安, 秦先梅. 重组人尿激酶原治疗急性肺栓塞的临床研究. 世界临床药物, 2018 , 39 (5) : 313 -317 . DOI: 10.13683/j.wph.2018.05.006
Qin-qin ZHANG, Zong-an LIANG, Xian-mei QIN. Clinical research of recombinant human prourokinase in the treatment of acute pulmonary embolism[J]. World Clinical Drug, 2018 , 39 (5) : 313 -317 . DOI: 10.13683/j.wph.2018.05.006
Year 2018 volume 39 Issue 5
12
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2018.05.006
  • Receive Date:2018-01-03
  • Online Date:2026-11-18
  • Published:2018-05-10
Article Data
Affiliations
History
  • Received:2018-01-03
  • Revised:2018-03-16
Affiliations
    1.Department of Respiratory and Critical Medical, West China School of Medicine/West China Hospital, Sichuan University, Chengdu 610041
    2.Department of Respiratory Medicine, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2018.05.006
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT